|
151
|
Rohaim MA, Clayton E, Sahin I, Vilela J, Khalifa ME, Al-Natour MQ, Bayoumi M, Poirier AC, Branavan M, Tharmakulasingam M, Chaudhry NS, Sodi R, Brown A, Burkhart P, Hacking W, Botham J, Boyce J, Wilkinson H, Williams C, Whittingham-Dowd J, Shaw E, Hodges M, Butler L, Bates MD, La Ragione R, Balachandran W, Fernando A, Munir M. Artificial Intelligence-Assisted Loop Mediated Isothermal Amplification (AI-LAMP) for Rapid Detection of SARS-CoV-2. Viruses 2020; 12:v12090972. [PMID: 32883050 PMCID: PMC7552048 DOI: 10.3390/v12090972] [Citation(s) in RCA: 29] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2020] [Revised: 08/22/2020] [Accepted: 08/24/2020] [Indexed: 01/13/2023] Open
Abstract
Until vaccines and effective therapeutics become available, the practical solution to transit safely out of the current coronavirus disease 19 (CoVID-19) lockdown may include the implementation of an effective testing, tracing and tracking system. However, this requires a reliable and clinically validated diagnostic platform for the sensitive and specific identification of SARS-CoV-2. Here, we report on the development of a de novo, high-resolution and comparative genomics guided reverse-transcribed loop-mediated isothermal amplification (LAMP) assay. To further enhance the assay performance and to remove any subjectivity associated with operator interpretation of results, we engineered a novel hand-held smart diagnostic device. The robust diagnostic device was further furnished with automated image acquisition and processing algorithms and the collated data was processed through artificial intelligence (AI) pipelines to further reduce the assay run time and the subjectivity of the colorimetric LAMP detection. This advanced AI algorithm-implemented LAMP (ai-LAMP) assay, targeting the RNA-dependent RNA polymerase gene, showed high analytical sensitivity and specificity for SARS-CoV-2. A total of ~200 coronavirus disease (CoVID-19)-suspected NHS patient samples were tested using the platform and it was shown to be reliable, highly specific and significantly more sensitive than the current gold standard qRT-PCR. Therefore, this system could provide an efficient and cost-effective platform to detect SARS-CoV-2 in resource-limited laboratories.
Collapse
Affiliation(s)
- Mohammed A. Rohaim
- Division of Biomedical and Life Sciences, Faculty of Health and Medicine, The Lancaster University, Lancaster LA1 4YW, UK; (M.A.R.); (E.C.); (I.S.); (J.V.); (M.E.K.); (M.Q.A.-N.); (M.B.); (J.W.-D.); (E.S.); (M.H.); (L.B.); (M.D.B.)
| | - Emily Clayton
- Division of Biomedical and Life Sciences, Faculty of Health and Medicine, The Lancaster University, Lancaster LA1 4YW, UK; (M.A.R.); (E.C.); (I.S.); (J.V.); (M.E.K.); (M.Q.A.-N.); (M.B.); (J.W.-D.); (E.S.); (M.H.); (L.B.); (M.D.B.)
| | - Irem Sahin
- Division of Biomedical and Life Sciences, Faculty of Health and Medicine, The Lancaster University, Lancaster LA1 4YW, UK; (M.A.R.); (E.C.); (I.S.); (J.V.); (M.E.K.); (M.Q.A.-N.); (M.B.); (J.W.-D.); (E.S.); (M.H.); (L.B.); (M.D.B.)
| | - Julianne Vilela
- Division of Biomedical and Life Sciences, Faculty of Health and Medicine, The Lancaster University, Lancaster LA1 4YW, UK; (M.A.R.); (E.C.); (I.S.); (J.V.); (M.E.K.); (M.Q.A.-N.); (M.B.); (J.W.-D.); (E.S.); (M.H.); (L.B.); (M.D.B.)
| | - Manar E. Khalifa
- Division of Biomedical and Life Sciences, Faculty of Health and Medicine, The Lancaster University, Lancaster LA1 4YW, UK; (M.A.R.); (E.C.); (I.S.); (J.V.); (M.E.K.); (M.Q.A.-N.); (M.B.); (J.W.-D.); (E.S.); (M.H.); (L.B.); (M.D.B.)
| | - Mohammad Q. Al-Natour
- Division of Biomedical and Life Sciences, Faculty of Health and Medicine, The Lancaster University, Lancaster LA1 4YW, UK; (M.A.R.); (E.C.); (I.S.); (J.V.); (M.E.K.); (M.Q.A.-N.); (M.B.); (J.W.-D.); (E.S.); (M.H.); (L.B.); (M.D.B.)
| | - Mahmoud Bayoumi
- Division of Biomedical and Life Sciences, Faculty of Health and Medicine, The Lancaster University, Lancaster LA1 4YW, UK; (M.A.R.); (E.C.); (I.S.); (J.V.); (M.E.K.); (M.Q.A.-N.); (M.B.); (J.W.-D.); (E.S.); (M.H.); (L.B.); (M.D.B.)
| | - Aurore C. Poirier
- Department of Pathology and Infectious Diseases, School of Veterinary Medicine, University of Surrey, Guildford GU2 7AL, UK; (A.C.P.); (R.L.R.)
| | - Manoharanehru Branavan
- College of Engineering, Design and Physical Sciences, Brunel University London, Kingston Lane, Uxbridge UB8 3PH, UK; (M.B.); (W.B.)
| | - Mukunthan Tharmakulasingam
- Centre for Vision, Speech and Signal Processing, University of Surrey, Guildford GU2 7XH, UK; (M.T.); (N.S.C.); (A.F.)
| | - Nouman S. Chaudhry
- Centre for Vision, Speech and Signal Processing, University of Surrey, Guildford GU2 7XH, UK; (M.T.); (N.S.C.); (A.F.)
| | - Ravinder Sodi
- Department of Biochemistry, Poole & Bournemouth Hospitals NHS Trust, Longfleet Road, Poole BH15 2JB, UK;
| | - Amy Brown
- The Royal Lancaster Infirmary, University Hospitals of Morecambe Bay NHS, Foundation Trust, Kendal LA9 7RG, UK; (A.B.); (P.B.); (W.H.); (J.B.); (J.B.); (H.W.); (C.W.)
| | - Peter Burkhart
- The Royal Lancaster Infirmary, University Hospitals of Morecambe Bay NHS, Foundation Trust, Kendal LA9 7RG, UK; (A.B.); (P.B.); (W.H.); (J.B.); (J.B.); (H.W.); (C.W.)
| | - Wendy Hacking
- The Royal Lancaster Infirmary, University Hospitals of Morecambe Bay NHS, Foundation Trust, Kendal LA9 7RG, UK; (A.B.); (P.B.); (W.H.); (J.B.); (J.B.); (H.W.); (C.W.)
| | - Judy Botham
- The Royal Lancaster Infirmary, University Hospitals of Morecambe Bay NHS, Foundation Trust, Kendal LA9 7RG, UK; (A.B.); (P.B.); (W.H.); (J.B.); (J.B.); (H.W.); (C.W.)
| | - Joe Boyce
- The Royal Lancaster Infirmary, University Hospitals of Morecambe Bay NHS, Foundation Trust, Kendal LA9 7RG, UK; (A.B.); (P.B.); (W.H.); (J.B.); (J.B.); (H.W.); (C.W.)
| | - Hayley Wilkinson
- The Royal Lancaster Infirmary, University Hospitals of Morecambe Bay NHS, Foundation Trust, Kendal LA9 7RG, UK; (A.B.); (P.B.); (W.H.); (J.B.); (J.B.); (H.W.); (C.W.)
| | - Craig Williams
- The Royal Lancaster Infirmary, University Hospitals of Morecambe Bay NHS, Foundation Trust, Kendal LA9 7RG, UK; (A.B.); (P.B.); (W.H.); (J.B.); (J.B.); (H.W.); (C.W.)
| | - Jayde Whittingham-Dowd
- Division of Biomedical and Life Sciences, Faculty of Health and Medicine, The Lancaster University, Lancaster LA1 4YW, UK; (M.A.R.); (E.C.); (I.S.); (J.V.); (M.E.K.); (M.Q.A.-N.); (M.B.); (J.W.-D.); (E.S.); (M.H.); (L.B.); (M.D.B.)
| | - Elisabeth Shaw
- Division of Biomedical and Life Sciences, Faculty of Health and Medicine, The Lancaster University, Lancaster LA1 4YW, UK; (M.A.R.); (E.C.); (I.S.); (J.V.); (M.E.K.); (M.Q.A.-N.); (M.B.); (J.W.-D.); (E.S.); (M.H.); (L.B.); (M.D.B.)
| | - Matt Hodges
- Division of Biomedical and Life Sciences, Faculty of Health and Medicine, The Lancaster University, Lancaster LA1 4YW, UK; (M.A.R.); (E.C.); (I.S.); (J.V.); (M.E.K.); (M.Q.A.-N.); (M.B.); (J.W.-D.); (E.S.); (M.H.); (L.B.); (M.D.B.)
| | - Lisa Butler
- Division of Biomedical and Life Sciences, Faculty of Health and Medicine, The Lancaster University, Lancaster LA1 4YW, UK; (M.A.R.); (E.C.); (I.S.); (J.V.); (M.E.K.); (M.Q.A.-N.); (M.B.); (J.W.-D.); (E.S.); (M.H.); (L.B.); (M.D.B.)
| | - Michelle D. Bates
- Division of Biomedical and Life Sciences, Faculty of Health and Medicine, The Lancaster University, Lancaster LA1 4YW, UK; (M.A.R.); (E.C.); (I.S.); (J.V.); (M.E.K.); (M.Q.A.-N.); (M.B.); (J.W.-D.); (E.S.); (M.H.); (L.B.); (M.D.B.)
| | - Roberto La Ragione
- Department of Pathology and Infectious Diseases, School of Veterinary Medicine, University of Surrey, Guildford GU2 7AL, UK; (A.C.P.); (R.L.R.)
| | - Wamadeva Balachandran
- College of Engineering, Design and Physical Sciences, Brunel University London, Kingston Lane, Uxbridge UB8 3PH, UK; (M.B.); (W.B.)
| | - Anil Fernando
- Centre for Vision, Speech and Signal Processing, University of Surrey, Guildford GU2 7XH, UK; (M.T.); (N.S.C.); (A.F.)
| | - Muhammad Munir
- Division of Biomedical and Life Sciences, Faculty of Health and Medicine, The Lancaster University, Lancaster LA1 4YW, UK; (M.A.R.); (E.C.); (I.S.); (J.V.); (M.E.K.); (M.Q.A.-N.); (M.B.); (J.W.-D.); (E.S.); (M.H.); (L.B.); (M.D.B.)
- Correspondence:
| |
Collapse
|
|
152
|
Lee JYH, Best N, McAuley J, Porter JL, Seemann T, Schultz MB, Sait M, Orlando N, Mercoulia K, Ballard SA, Druce J, Tran T, Catton MG, Pryor MJ, Cui HL, Luttick A, McDonald S, Greenhalgh A, Kwong JC, Sherry NL, Graham M, Hoang T, Herisse M, Pidot SJ, Williamson DA, Howden BP, Monk IR, Stinear TP. Validation of a single-step, single-tube reverse transcription loop-mediated isothermal amplification assay for rapid detection of SARS-CoV-2 RNA. J Med Microbiol 2020; 69:1169-1178. [PMID: 32755529 PMCID: PMC7656183 DOI: 10.1099/jmm.0.001238] [Citation(s) in RCA: 50] [Impact Index Per Article: 12.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2020] [Accepted: 07/10/2020] [Indexed: 12/21/2022] Open
Abstract
Introduction. The SARS-CoV-2 pandemic of 2020 has resulted in unparalleled requirements for RNA extraction kits and enzymes required for virus detection, leading to global shortages. This has necessitated the exploration of alternative diagnostic options to alleviate supply chain issues.Aim. To establish and validate a reverse transcription loop-mediated isothermal amplification (RT- LAMP) assay for the detection of SARS-CoV-2 from nasopharyngeal swabs.Methodology. We used a commercial RT-LAMP mastermix from OptiGene in combination with a primer set designed to detect the CDC N1 region of the SARS-CoV-2 nucleocapsid (N) gene. A single-tube, single-step fluorescence assay was implemented whereby 1 µl of universal transport medium (UTM) directly from a nasopharyngeal swab could be used as template, bypassing the requirement for RNA purification. Amplification and detection could be conducted in any thermocycler capable of holding 65 °C for 30 min and measure fluorescence in the FAM channel at 1 min intervals.Results. Assay evaluation by assessment of 157 clinical specimens previously screened by E-gene RT-qPCR revealed assay sensitivity and specificity of 87 and 100%, respectively. Results were fast, with an average time-to-positive (Tp) for 93 clinical samples of 14 min (sd±7 min). Using dilutions of SARS-CoV-2 virus spiked into UTM, we also evaluated assay performance against FDA guidelines for implementation of emergency-use diagnostics and established a limit-of-detection of 54 Tissue Culture Infectious Dose 50 per ml (TCID50 ml-1), with satisfactory assay sensitivity and specificity. A comparison of 20 clinical specimens between four laboratories showed excellent interlaboratory concordance; performing equally well on three different, commonly used thermocyclers, pointing to the robustness of the assay.Conclusion. With a simplified workflow, The N1 gene Single Tube Optigene LAMP assay (N1-STOP-LAMP) is a powerful, scalable option for specific and rapid detection of SARS-CoV-2 and an additional resource in the diagnostic armamentarium against COVID-19.
Collapse
Affiliation(s)
- Jean Y. H. Lee
- Department of Microbiology and Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia
- Department of Infectious Diseases, Monash Health, Clayton, Victoria, Australia
| | - Nickala Best
- GenWorks Pty Ltd, Thebarton, South Australia, Australia
| | - Julie McAuley
- Department of Microbiology and Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia
| | - Jessica L. Porter
- Department of Microbiology and Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia
| | - Torsten Seemann
- Department of Microbiology and Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia
- Microbiological Diagnostic Unit Public Health Laboratory, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia
| | - Mark B. Schultz
- Microbiological Diagnostic Unit Public Health Laboratory, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia
| | - Michelle Sait
- Microbiological Diagnostic Unit Public Health Laboratory, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia
| | - Nicole Orlando
- Microbiological Diagnostic Unit Public Health Laboratory, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia
| | - Karolina Mercoulia
- Microbiological Diagnostic Unit Public Health Laboratory, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia
| | - Susan A. Ballard
- Microbiological Diagnostic Unit Public Health Laboratory, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia
| | - Julian Druce
- Victorian Infectious Diseases Reference Laboratory, Melbourne Health at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia
| | - Thomas Tran
- Victorian Infectious Diseases Reference Laboratory, Melbourne Health at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia
| | - Mike G. Catton
- Victorian Infectious Diseases Reference Laboratory, Melbourne Health at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia
| | | | | | | | - Sean McDonald
- GenWorks Pty Ltd, Thebarton, South Australia, Australia
| | | | - Jason C. Kwong
- Department of Microbiology and Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia
- Department of Infectious Diseases, Austin Health, Heidelberg, Victoria, Australia
| | - Norelle L. Sherry
- Microbiological Diagnostic Unit Public Health Laboratory, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia
- Department of Infectious Diseases, Austin Health, Heidelberg, Victoria, Australia
| | - Maryza Graham
- Department of Microbiology, Monash Health, Clayton, Victoria, Australia
| | - Tuyet Hoang
- Department of Microbiology and Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia
- Microbiological Diagnostic Unit Public Health Laboratory, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia
| | - Marion Herisse
- Department of Microbiology and Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia
| | - Sacha J. Pidot
- Department of Microbiology and Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia
| | - Deborah A. Williamson
- Department of Microbiology and Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia
- Microbiological Diagnostic Unit Public Health Laboratory, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia
- Melbourne Health, Melbourne, Victoria, Australia
| | - Benjamin P. Howden
- Department of Microbiology and Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia
- Microbiological Diagnostic Unit Public Health Laboratory, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia
- Department of Infectious Diseases, Austin Health, Heidelberg, Victoria, Australia
| | - Ian R. Monk
- Department of Microbiology and Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia
| | - Timothy P. Stinear
- Department of Microbiology and Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia
| |
Collapse
|
|
153
|
Basiri A, Heidari A, Nadi MF, Fallahy MTP, Nezamabadi SS, Sedighi M, Saghazadeh A, Rezaei N. Microfluidic devices for detection of RNA viruses. Rev Med Virol 2020; 31:1-11. [PMID: 32844526 PMCID: PMC7460878 DOI: 10.1002/rmv.2154] [Citation(s) in RCA: 65] [Impact Index Per Article: 16.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2020] [Revised: 07/21/2020] [Accepted: 07/22/2020] [Indexed: 12/12/2022]
Abstract
There is a long way to go before the coronavirus disease 2019 (Covid‐19) outbreak comes under control. qRT‐PCR is currently used for the detection of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), the causative agent of Covid‐19, but it is expensive, time‐consuming, and not as sensitive as it should be. Finding a rapid, easy‐to‐use, and cheap diagnostic method is necessary to help control the current outbreak. Microfluidic systems provide a platform for many diagnostic tests, including RT‐PCR, RT‐LAMP, nested‐PCR, nucleic acid hybridization, ELISA, fluorescence‐Based Assays, rolling circle amplification, aptamers, sample preparation multiplexer (SPM), Porous Silicon Nanowire Forest, silica sol‐gel coating/bonding, and CRISPR. They promise faster, cheaper, and easy‐to‐use methods with higher sensitivity, so microfluidic devices have a high potential to be an alternative method for the detection of viral RNA. These devices have previously been used to detect RNA viruses such as H1N1, Zika, HAV, HIV, and norovirus, with acceptable results. This paper provides an overview of microfluidic systems as diagnostic methods for RNA viruses with a focus on SARS‐CoV‐2.
Collapse
Affiliation(s)
- Arefeh Basiri
- Department of Biomaterials and Tissue Engineering, School of Advanced Technology in Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.,Systematic Review and Meta-analysis Expert Group (SRMEG), Universal Scientific Education and Research Network (USERN), Tehran, Iran
| | - Arash Heidari
- Systematic Review and Meta-analysis Expert Group (SRMEG), Universal Scientific Education and Research Network (USERN), Tehran, Iran.,School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
| | - Melina Farshbaf Nadi
- Systematic Review and Meta-analysis Expert Group (SRMEG), Universal Scientific Education and Research Network (USERN), Tehran, Iran.,School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
| | - Mohammad Taha Pahlevan Fallahy
- Systematic Review and Meta-analysis Expert Group (SRMEG), Universal Scientific Education and Research Network (USERN), Tehran, Iran.,School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
| | - Sasan Salehi Nezamabadi
- Systematic Review and Meta-analysis Expert Group (SRMEG), Universal Scientific Education and Research Network (USERN), Tehran, Iran.,School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
| | - Mohammadreza Sedighi
- Systematic Review and Meta-analysis Expert Group (SRMEG), Universal Scientific Education and Research Network (USERN), Tehran, Iran.,School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
| | - Amene Saghazadeh
- Systematic Review and Meta-analysis Expert Group (SRMEG), Universal Scientific Education and Research Network (USERN), Tehran, Iran.,Research Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran
| | - Nima Rezaei
- Research Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran.,Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.,Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Tehran, Iran
| |
Collapse
|
|
154
|
Andryukov BG. Six decades of lateral flow immunoassay: from determining metabolic markers to diagnosing COVID-19. AIMS Microbiol 2020; 6:280-304. [PMID: 33134745 PMCID: PMC7595842 DOI: 10.3934/microbiol.2020018] [Citation(s) in RCA: 92] [Impact Index Per Article: 23.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2020] [Accepted: 08/20/2020] [Indexed: 01/10/2023] Open
Abstract
Technologies based on lateral flow immunoassay (LFIA), known in some countries of the world as immunochromatographic tests, have been successfully used for the last six decades in diagnostics of many diseases and conditions as they allow rapid detection of molecular ligands in biosubstrates. The popularity of these diagnostic platforms is constantly increasing in healthcare facilities, particularly those facing limited budgets and time, as well as in household use for individual health monitoring. The advantages of these low-cost devices over modern laboratory-based analyzers come from their availability, opportunity of rapid detection, and ease of use. The attractiveness of these portable diagnostic tools is associated primarily with their high analytical sensitivity and specificity, as well as with the easy visual readout of results. These qualities explain the growing popularity of LFIA in developing countries, when applied at small hospitals, in emergency situations where screening and monitoring health condition is crucially important, and as well as for self-testing of patients. These tools have passed the test of time, and now LFIA test systems are fully consistent with the world's modern concept of ‘point-of-care testing’, finding a wide range of applications not only in human medicine, but also in ecology, veterinary medicine, and agriculture. The extensive opportunities provided by LFIA contribute to the continuous development and improvement of this technology and to the creation of new-generation formats. This review will highlight the modern principles of design of the most widely used formats of test-systems for clinical laboratory diagnostics, summarize the main advantages and disadvantages of the method, as well as the current achievements and prospects of the LFIA technology. The latest innovations are aimed at improving the analytical performance of LFIA platforms for the diagnosis of bacterial and viral infections, including COVID-19.
Collapse
Affiliation(s)
- Boris G Andryukov
- Somov Research Institute of Epidemiology and Microbiology, Vladivostok, Russian Federation.,Far Eastern Federal University (FEFU), Vladivostok, Russian Federation
| |
Collapse
|
|
155
|
Ali Z, Aman R, Mahas A, Rao GS, Tehseen M, Marsic T, Salunke R, Subudhi AK, Hala SM, Hamdan SM, Pain A, Alofi FS, Alsomali A, Hashem AM, Khogeer A, Almontashiri NAM, Abedalthagafi M, Hassan N, Mahfouz MM. iSCAN: An RT-LAMP-coupled CRISPR-Cas12 module for rapid, sensitive detection of SARS-CoV-2. Virus Res 2020; 288:198129. [PMID: 32822689 PMCID: PMC7434412 DOI: 10.1016/j.virusres.2020.198129] [Citation(s) in RCA: 192] [Impact Index Per Article: 48.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/04/2020] [Revised: 08/11/2020] [Accepted: 08/12/2020] [Indexed: 12/26/2022]
Abstract
The COVID-19 pandemic caused by SARS-CoV-2 affects all aspects of human life. Detection platforms that are efficient, rapid, accurate, specific, sensitive, and user friendly are urgently needed to manage and control the spread of SARS-CoV-2. RT-qPCR based methods are the gold standard for SARS-CoV-2 detection. However, these methods require trained personnel, sophisticated infrastructure, and a long turnaround time, thereby limiting their usefulness. Reverse transcription-loop-mediated isothermal amplification (RT-LAMP), a one-step nucleic acid amplification method conducted at a single temperature, has been used for colorimetric virus detection. CRISPR-Cas12 and CRISPR-Cas13 systems, which possess collateral activity against ssDNA and RNA, respectively, have also been harnessed for virus detection. Here, we built an efficient, rapid, specific, sensitive, user-friendly SARS-CoV-2 detection module that combines the robust virus amplification of RT-LAMP with the specific detection ability of SARS-CoV-2 by CRISPR-Cas12. Furthermore, we combined the RT-LAMP-CRISPR-Cas12 module with lateral flow cells to enable highly efficient point-of-care SARS-CoV-2 detection. Our iSCAN SARS-CoV-2 detection module, which exhibits the critical features of a robust molecular diagnostic device, should facilitate the effective management and control of COVID-19.
Collapse
Affiliation(s)
- Zahir Ali
- Laboratory for Genome Engineering and Synthetic Biology, Division of Biological Sciences, 4700 King Abdullah University of Science and Technology, Thuwal, 23955-6900, Saudi Arabia
| | - Rashid Aman
- Laboratory for Genome Engineering and Synthetic Biology, Division of Biological Sciences, 4700 King Abdullah University of Science and Technology, Thuwal, 23955-6900, Saudi Arabia
| | - Ahmed Mahas
- Laboratory for Genome Engineering and Synthetic Biology, Division of Biological Sciences, 4700 King Abdullah University of Science and Technology, Thuwal, 23955-6900, Saudi Arabia
| | - Gundra Sivakrishna Rao
- Laboratory for Genome Engineering and Synthetic Biology, Division of Biological Sciences, 4700 King Abdullah University of Science and Technology, Thuwal, 23955-6900, Saudi Arabia
| | - Muhammad Tehseen
- Laboratory of DNA Replication and Recombination, Biological and Environmental Sciences and Engineering Division, King Abdullah University of Science and Technology (KAUST), Thuwal, 23955-6900, Saudi Arabia
| | - Tin Marsic
- Laboratory for Genome Engineering and Synthetic Biology, Division of Biological Sciences, 4700 King Abdullah University of Science and Technology, Thuwal, 23955-6900, Saudi Arabia
| | - Rahul Salunke
- Pathogen Genomics Laboratory, BESE Division, King Abdullah University of Science and Technology (KAUST), Thuwal, Saudi Arabia
| | - Amit K Subudhi
- Pathogen Genomics Laboratory, BESE Division, King Abdullah University of Science and Technology (KAUST), Thuwal, Saudi Arabia
| | - Sharif M Hala
- Pathogen Genomics Laboratory, BESE Division, King Abdullah University of Science and Technology (KAUST), Thuwal, Saudi Arabia; King Abdullah International Medical Research Centre - Ministry of National Guard Health Affairs, Jeddah, Saudi Arabia; King Saud bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia
| | - Samir M Hamdan
- Laboratory of DNA Replication and Recombination, Biological and Environmental Sciences and Engineering Division, King Abdullah University of Science and Technology (KAUST), Thuwal, 23955-6900, Saudi Arabia
| | - Arnab Pain
- Pathogen Genomics Laboratory, BESE Division, King Abdullah University of Science and Technology (KAUST), Thuwal, Saudi Arabia
| | - Fadwa S Alofi
- Infectious Diseases Department, King Fahad Hospital, Madinah, Saudi Arabia
| | - Afrah Alsomali
- King Abdullah Medical Complex (KAMC), Jeddah, Saudi Arabia
| | - Anwar M Hashem
- Vaccines and Immunotherapy Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia; Department of Medical Microbiology and Parasitology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia
| | - Asim Khogeer
- Plan and Research Department, General Directorate of Health Affairs Makkah Region, MOH, Saudi Arabia
| | - Naif A M Almontashiri
- College of Applied Medical Sciences and Center for Genetics and Inherited Diseases, Taibah University, Madinah, Saudi Arabia
| | - Malak Abedalthagafi
- King Fahad Medical City and King Abdulaziz City for Science and Technology, Riyadh, Saudi Arabia
| | - Norhan Hassan
- Laboratory for Genome Engineering and Synthetic Biology, Division of Biological Sciences, 4700 King Abdullah University of Science and Technology, Thuwal, 23955-6900, Saudi Arabia
| | - Magdy M Mahfouz
- Laboratory for Genome Engineering and Synthetic Biology, Division of Biological Sciences, 4700 King Abdullah University of Science and Technology, Thuwal, 23955-6900, Saudi Arabia.
| |
Collapse
|
|
156
|
Araujo JO, Valente J, Kooistra L, Munniks S, Peters RJB. Experimental Flight Patterns Evaluation for a UAV-Based Air Pollutant Sensor. MICROMACHINES 2020; 11:mi11080768. [PMID: 32796583 PMCID: PMC7464112 DOI: 10.3390/mi11080768] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 06/30/2020] [Revised: 08/08/2020] [Accepted: 08/08/2020] [Indexed: 02/04/2023]
Abstract
The use of drones in combination with remote sensors have displayed increasing interest over the last years due to its potential to automate monitoring processes. In this study, a novel approach of a small flying e-nose is proposed by assembling a set of AlphaSense electrochemical-sensors to a DJI Matrix 100 unmanned aerial vehicle (UAV). The system was tested on an outdoor field with a source of NO2. Field tests were conducted in a 100 m2 area on two dates with different wind speed levels varying from low (0.0–2.9m/s) to high (2.1–5.3m/s), two flight patterns zigzag and spiral and at three altitudes (3, 6 and 9 m). The objective of this study is to evaluate the sensors responsiveness and performance when subject to distinct flying conditions. A Wilcoxon rank-sum test showed significant difference between flight patterns only under High Wind conditions, with Spiral flights being slightly superior than Zigzag. With the aim of contributing to other studies in the same field, the data used in this analysis will be shared with the scientific community.
Collapse
Affiliation(s)
- João Otávio Araujo
- Information Technology (INF), Wageningen University (WUR), Hollandseweg 1, 6706 KN Wageningen, The Netherlands;
| | - João Valente
- Information Technology (INF), Wageningen University (WUR), Hollandseweg 1, 6706 KN Wageningen, The Netherlands;
- Correspondence: ; Tel.: +31-628-398-164
| | - Lammert Kooistra
- Laboratory of Geo-Information Science and Remote Sensing, Wageningen University (WUR), Droevendaalsesteeg 3, 6708 PB Wageningen, The Netherlands;
| | - Sandra Munniks
- Wageningen Food Safety Research (WFSR), Akkermaalsbos 2, 6708 WB Wageningen, The Netherlands; (S.M.); (R.J.B.P.)
| | - Ruud J. B. Peters
- Wageningen Food Safety Research (WFSR), Akkermaalsbos 2, 6708 WB Wageningen, The Netherlands; (S.M.); (R.J.B.P.)
| |
Collapse
|
|
157
|
Newly developed diagnostic methods for SARS-CoV-2 detection. TURKISH JOURNAL OF BIOCHEMISTRY 2020. [DOI: 10.1515/tjb-2020-0218] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
AbstractThe emergence of SARS-CoV-2, responsible for COVID-19 disease, has caused a substantial worldwide pandemic and has become a significant public health problem. World Health Organization (WHO) has declared COVID-19 as a devastating health emergency for all countries. Public health officials continue to monitor the situation closely to control this new virus-related outbreak. In order to continue to manage this pandemic, a fast and sensitive diagnosis of COVID-19 is attempted. Emerging tests have become an essential part of the management of the COVID-19 crisis. This review article aims to provide a detailed explanation of ongoing and new diagnostic technologies for SARS-CoV-2 and a summary of method principles. Examples of new diagnostic methods for providing efficient and rapid diagnostic tests for managing the SARS-CoV-2 outbreak are also mentioned.
Collapse
|
|
158
|
Alsuliman T, Sulaiman R, Ismail S, Srour M, Alrstom A. COVID-19 paraclinical diagnostic tools: Updates and future trends. Curr Res Transl Med 2020; 68:83-91. [PMID: 32576508 PMCID: PMC7305905 DOI: 10.1016/j.retram.2020.06.001] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2020] [Revised: 05/24/2020] [Accepted: 06/15/2020] [Indexed: 02/08/2023]
Abstract
MOTIVATION COVID-19 is one of the most widely affecting pandemics. As for many respiratory viruses-caused diseases, diagnosis of COVID-19 relies on two main compartments: clinical and paraclinical diagnostic criteria. Rapid and accurate diagnosis is vital in such a pandemic. On one side, rapidity may enhance management effectiveness, while on the other, coupling efficiency and less costly procedures may permit more effective community-scale management. METHODOLOGY AND MAIN STRUCTURE In this review, we shed light on the most used and the most validated diagnostic tools. Furthermore, we intend to include few under-development techniques that may be potentially useful in this context. The practical intent of our work is to provide clinicians with a realistic summarized review of the essential elements in the applied paraclinical diagnosis of COVID-19.
Collapse
Affiliation(s)
- Tamim Alsuliman
- Service d'hématologie, hôpital Saint-Antoine, AP-HP Sorbonne Université, 75012, Paris, France.
| | - Rand Sulaiman
- Department of Genetics, Institute of Fundamental Medicine and Biology, Kazan Federal University, Kazan, Russian Federation
| | - Sawsan Ismail
- Department of Pathology, Faculty of Medicine, Tishreen University, Lattakia, Syria
| | - Micha Srour
- Service maladie du sang, centre hospitalier universitaire de Lille, 59000, Lille, France
| | - Ali Alrstom
- Department of Infectious Diseases, Faculty of Medicine, Damascus University, Damascus, Syria
| |
Collapse
|
|
159
|
Rubulotta F, Soliman-Aboumarie H, Filbey K, Geldner G, Kuck K, Ganau M, Hemmerling TM. Technologies to Optimize the Care of Severe COVID-19 Patients for Health Care Providers Challenged by Limited Resources. Anesth Analg 2020. [PMID: 32433248 DOI: 10.1213/ane.0000000000004985.pmid:32433248;pmcid:pmc7258840] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/14/2023]
Abstract
Health care systems are belligerently responding to the new coronavirus disease 2019 (COVID-19). The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a specific condition, whose distinctive features are severe hypoxemia associated with (>50% of cases) normal respiratory system compliance. When a patient requires intubation and invasive ventilation, the outcome is poor, and the length of stay in the intensive care unit (ICU) is usually 2 or 3 weeks. In this article, the authors review several technological devices, which could support health care providers at the bedside to optimize the care for COVID-19 patients who are sedated, paralyzed, and ventilated. Particular attention is provided to the use of videolaryngoscopes (VL) because these can assist anesthetists to perform a successful intubation outside the ICU while protecting health care providers from this viral infection. Authors will also review processed electroencephalographic (EEG) monitors which are used to better titrate sedation and the train-of-four monitors which are utilized to better administer neuromuscular blocking agents in the view of sparing limited pharmacological resources. COVID-19 can rapidly exhaust human and technological resources too within the ICU. This review features a series of technological advancements that can significantly improve the care of patients requiring isolation. The working conditions in isolation could cause gaps or barriers in communication, fatigue, and poor documentation of provided care. The available technology has several advantages including (a) facilitating appropriate paperless documentation and communication between all health care givers working in isolation rooms or large isolation areas; (b) testing patients and staff at the bedside using smart point-of-care diagnostics (SPOCD) to confirm COVID-19 infection; (c) allowing diagnostics and treatment at the bedside through point-of-care ultrasound (POCUS) and thromboelastography (TEG); (d) adapting the use of anesthetic machines and the use of volatile anesthetics. Implementing technologies for safeguarding health care providers as well as monitoring the limited pharmacological resources are paramount. Only by leveraging new technologies, it will be possible to sustain and support health care systems during the expected long course of this pandemic.
Collapse
Affiliation(s)
- Francesca Rubulotta
- From the Department of Anaesthesia and Intensive Care Medicine, Imperial College London, London, United Kingdom
| | - Hatem Soliman-Aboumarie
- Department of Anaesthetics and Critical Care, Harefield Hospital, Royal Brompton and Harefield National Health System (NHS) Foundation Trust, London, United Kingdom
| | - Kevin Filbey
- Department of Anesthesia, Intensive Care Medicine, Chronic Pain and Emergency Medicine, Ludwigsburg Hospital, Ludwigsburg, Germany
| | - Goetz Geldner
- Department of Anesthesia, Intensive Care Medicine, Chronic Pain and Emergency Medicine, Ludwigsburg Hospital, Ludwigsburg, Germany
| | - Kai Kuck
- Department of Anesthesiology and Bioengineering, University of Utah, Salt Lake City, Utah
| | - Mario Ganau
- Department of Neurosurgery, John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom
| | | |
Collapse
|
|
160
|
Rubulotta F, Soliman-Aboumarie H, Filbey K, Geldner G, Kuck K, Ganau M, Hemmerling TM. Technologies to Optimize the Care of Severe COVID-19 Patients for Health Care Providers Challenged by Limited Resources. Anesth Analg 2020; 131:351-364. [PMID: 32433248 PMCID: PMC7258840 DOI: 10.1213/ane.0000000000004985] [Citation(s) in RCA: 31] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/14/2020] [Indexed: 12/13/2022]
Abstract
Health care systems are belligerently responding to the new coronavirus disease 2019 (COVID-19). The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a specific condition, whose distinctive features are severe hypoxemia associated with (>50% of cases) normal respiratory system compliance. When a patient requires intubation and invasive ventilation, the outcome is poor, and the length of stay in the intensive care unit (ICU) is usually 2 or 3 weeks. In this article, the authors review several technological devices, which could support health care providers at the bedside to optimize the care for COVID-19 patients who are sedated, paralyzed, and ventilated. Particular attention is provided to the use of videolaryngoscopes (VL) because these can assist anesthetists to perform a successful intubation outside the ICU while protecting health care providers from this viral infection. Authors will also review processed electroencephalographic (EEG) monitors which are used to better titrate sedation and the train-of-four monitors which are utilized to better administer neuromuscular blocking agents in the view of sparing limited pharmacological resources. COVID-19 can rapidly exhaust human and technological resources too within the ICU. This review features a series of technological advancements that can significantly improve the care of patients requiring isolation. The working conditions in isolation could cause gaps or barriers in communication, fatigue, and poor documentation of provided care. The available technology has several advantages including (a) facilitating appropriate paperless documentation and communication between all health care givers working in isolation rooms or large isolation areas; (b) testing patients and staff at the bedside using smart point-of-care diagnostics (SPOCD) to confirm COVID-19 infection; (c) allowing diagnostics and treatment at the bedside through point-of-care ultrasound (POCUS) and thromboelastography (TEG); (d) adapting the use of anesthetic machines and the use of volatile anesthetics. Implementing technologies for safeguarding health care providers as well as monitoring the limited pharmacological resources are paramount. Only by leveraging new technologies, it will be possible to sustain and support health care systems during the expected long course of this pandemic.
Collapse
Affiliation(s)
- Francesca Rubulotta
- From the Department of Anaesthesia and Intensive Care Medicine, Imperial College London, London, United Kingdom
| | - Hatem Soliman-Aboumarie
- Department of Anaesthetics and Critical Care, Harefield Hospital, Royal Brompton and Harefield NHS Foundation Trust, London, United Kingdom
| | - Kevin Filbey
- Department of Anesthesia, Intensive Care Medicine, Chronic Pain and Emergency Medicine, Ludwigsburg Hospital, Ludwigsburg, Germany
| | - Goetz Geldner
- Department of Anesthesia, Intensive Care Medicine, Chronic Pain and Emergency Medicine, Ludwigsburg Hospital, Ludwigsburg, Germany
| | - Kai Kuck
- Department of Anesthesiology and Bioengineering, University of Utah
| | - Mario Ganau
- Department of Neurosurgery, John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom
| | | |
Collapse
|
|
161
|
Santaella-Tenorio J. SARS-CoV-2 diagnostic testing alternatives for Latin America. Colomb Med (Cali) 2020; 51:e4272. [PMID: 33012887 PMCID: PMC7518727 DOI: 10.25100/cm.v51i2.4272] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/02/2020] [Revised: 04/25/2020] [Accepted: 05/04/2020] [Indexed: 12/28/2022] Open
Abstract
In the past four months SARS-CoV-2 has reached most countries in the world. Public health strategies based on widespread testing and proper isolation of positive cases have shown to be helpful to reduce local transmission of SARS-CoV-2. Confirmatory tests, that identify viral RNA, and screening serological tests that identify viral antigens or host antibodies against viral proteins are part of the tools that nations can use to fight infectious disease epidemics. Understanding how each test works can provide insights about their test characteristics and how they can be used for different clinical and public health goals. Testing is a key strategy to reduce viral transmission, not only for this epidemic, but also for others to come.
Collapse
Affiliation(s)
- Julián Santaella-Tenorio
- Universidad del Valle; Escuela de Salud Pública, Facultad de Salud. Cali, Colombia
- Pontificia Universidad Javeriana, Maestría en Epidemiología Clínica, Cali, Colombia
| |
Collapse
|
|
162
|
Palestino G, García-Silva I, González-Ortega O, Rosales-Mendoza S. Can nanotechnology help in the fight against COVID-19? Expert Rev Anti Infect Ther 2020; 18:849-864. [PMID: 32574081 DOI: 10.1080/14787210.2020.1776115] [Citation(s) in RCA: 41] [Impact Index Per Article: 10.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
INTRODUCTION The current COVID-19 pandemic caused by the SARS-CoV-2 virus demands the development of strategies not only to detect or inactivate the virus, but to treat it (therapeutically and prophylactically). COVID-19 is not only a critical threat for the population with risk factors, but also generates a dramatic economic impact in terms of morbidity and the overall interruption of economic activities. AREAS COVERED Advanced materials are the basis of several technologies that could diminish the impact of COVID-19: biosensors might allow early virus detection, nanosized vaccines are powerful agents that could prevent viral infections, and nanosystems with antiviral activity could bind the virus for inactivation or destruction upon application of an external stimulus. Herein all these methods are discussed under the light of cutting-edge technologies and the previously reported prototypes targeting enveloped viruses similar to SARS-CoV-2. This analysis was derived from an extensive scientific literature search (including pubmed) performed on April 2020. EXPERT OPINION Perspectives on how biosensors, vaccines, and antiviral nanosystems can be implemented to fight COVID-19 are envisioned; identifying the approaches that can be implemented in the short term and those that deserve long term research to cope with respiratory viruses-related pandemics in the future.
Collapse
Affiliation(s)
- Gabriela Palestino
- Facultad De Ciencias Químicas, Universidad Autónoma De San Luis Potosí , San Luis Potosí, México.,Sección De Biotecnología, Centro De Investigación En Ciencias De La Salud Y Biomedicina, Universidad Autónoma De San Luis Potosí , San Luis Potosí, México
| | - Ileana García-Silva
- Facultad De Ciencias Químicas, Universidad Autónoma De San Luis Potosí , San Luis Potosí, México.,Sección De Biotecnología, Centro De Investigación En Ciencias De La Salud Y Biomedicina, Universidad Autónoma De San Luis Potosí , San Luis Potosí, México
| | - Omar González-Ortega
- Facultad De Ciencias Químicas, Universidad Autónoma De San Luis Potosí , San Luis Potosí, México
| | - Sergio Rosales-Mendoza
- Facultad De Ciencias Químicas, Universidad Autónoma De San Luis Potosí , San Luis Potosí, México.,Sección De Biotecnología, Centro De Investigación En Ciencias De La Salud Y Biomedicina, Universidad Autónoma De San Luis Potosí , San Luis Potosí, México
| |
Collapse
|
|
163
|
Azizipour N, Avazpour R, Rosenzweig DH, Sawan M, Ajji A. Evolution of Biochip Technology: A Review from Lab-on-a-Chip to Organ-on-a-Chip. MICROMACHINES 2020; 11:E599. [PMID: 32570945 PMCID: PMC7345732 DOI: 10.3390/mi11060599] [Citation(s) in RCA: 98] [Impact Index Per Article: 24.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 05/02/2020] [Revised: 06/09/2020] [Accepted: 06/16/2020] [Indexed: 12/21/2022]
Abstract
Following the advancements in microfluidics and lab-on-a-chip (LOC) technologies, a novel biomedical application for microfluidic based devices has emerged in recent years and microengineered cell culture platforms have been created. These micro-devices, known as organ-on-a-chip (OOC) platforms mimic the in vivo like microenvironment of living organs and offer more physiologically relevant in vitro models of human organs. Consequently, the concept of OOC has gained great attention from researchers in the field worldwide to offer powerful tools for biomedical researches including disease modeling, drug development, etc. This review highlights the background of biochip development. Herein, we focus on applications of LOC devices as a versatile tool for POC applications. We also review current progress in OOC platforms towards body-on-a-chip, and we provide concluding remarks and future perspectives for OOC platforms for POC applications.
Collapse
Affiliation(s)
- Neda Azizipour
- Institut de Génie Biomédical, Polytechnique Montréal, Montreal, QC H3C 3A7, Canada;
| | - Rahi Avazpour
- Department of Chemical Engineering, Polytechnique Montréal, Montreal, QC H3C 3A7, Canada;
| | - Derek H. Rosenzweig
- Department of Surgery, McGill University, Montreal, QC H3G 1A4, Canada;
- Injury, Repair and Recovery Program, Research Institute of McGill University Health Centre, Montreal, QC H3H 2R9, Canada
| | - Mohamad Sawan
- Polystim Neurotech Laboratory, Electrical Engineering Department, Polytechnique Montreal, QC H3T 1J4, Canada
- CenBRAIN Laboratory, School of Engineering, Westlake Institute for Advanced Study, Westlake University, Hangzhou 310024, China
| | - Abdellah Ajji
- Institut de Génie Biomédical, Polytechnique Montréal, Montreal, QC H3C 3A7, Canada;
- NSERC-Industry Chair, CREPEC, Chemical Engineering Department, Polytechnique Montreal, Montreal, QC H3C 3A7, Canada
| |
Collapse
|
|
164
|
Wee SK, Sivalingam SP, Yap EPH. Rapid Direct Nucleic Acid Amplification Test without RNA Extraction for SARS-CoV-2 Using a Portable PCR Thermocycler. Genes (Basel) 2020; 11:E664. [PMID: 32570810 PMCID: PMC7349311 DOI: 10.3390/genes11060664] [Citation(s) in RCA: 58] [Impact Index Per Article: 14.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2020] [Revised: 06/02/2020] [Accepted: 06/16/2020] [Indexed: 12/20/2022] Open
Abstract
There is an ongoing worldwide coronavirus disease 2019 (Covid-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). At present, confirmatory diagnosis is by reverse transcription polymerase chain reaction (RT-PCR), typically taking several hours and requiring a molecular laboratory to perform. There is an urgent need for rapid, simplified, and cost-effective detection methods. We have developed and analytically validated a protocol for direct rapid extraction-free PCR (DIRECT-PCR) detection of SARS-CoV-2 without the need for nucleic acid purification. As few as six RNA copies per reaction of viral nucleocapsid (N) gene from respiratory samples such as sputum and nasal exudate can be detected directly using our one-step inhibitor-resistant assay. The performance of this assay was validated on a commercially available portable PCR thermocycler. Viral lysis, reverse transcription, amplification, and detection are achieved in a single-tube homogeneous reaction within 36 min. This minimizes hands-on time, reduces turnaround-time for sample-to-result, and obviates the need for RNA purification reagents. It could enable wider use of Covid-19 testing for diagnosis, screening, and research in countries and regions where laboratory capabilities are limiting.
Collapse
Affiliation(s)
| | | | - Eric Peng Huat Yap
- Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore 308232, Singapore; (S.K.W.); (S.P.S.)
| |
Collapse
|
|
165
|
James AS, Alwneh JI. COVID-19 Infection Diagnosis: Potential Impact of Isothermal Amplification Technology to Reduce Community Transmission of SARS-CoV-2. Diagnostics (Basel) 2020; 10:E399. [PMID: 32545412 PMCID: PMC7345291 DOI: 10.3390/diagnostics10060399] [Citation(s) in RCA: 55] [Impact Index Per Article: 13.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2020] [Revised: 05/30/2020] [Accepted: 06/05/2020] [Indexed: 01/08/2023] Open
Abstract
The current coronavirus disease 2019 (COVID-19) pandemic is largely driven by community transmission, after 2019 novel Coronavirus (2019-nCoV or SARS-CoV-2) crosses the borders. To stop the spread, rapid testing is required at community clinics and hospitals. These rapid tests should be comparable with the standard PCR technology. Isothermal amplification technology provides an excellent alternative that is highly amenable to resource limited settings, where expertise and infrastructure to support PCR are not available. In this review, we provide a brief description of isothermal amplification technology, its potential and the gaps that need to be considered for SARS-CoV-2 detection. Among this emerging technology, loop-mediated amplification (LAMP), recombinase polymerase amplification (RPA) and Nicking enzyme-assisted reaction (NEAR) technologies have been identified as potential platforms that could be implemented at community level, without samples referral to a centralized laboratory and prolonged turnaround time associated with the standard COVID-19 RT-PCR test. LAMP, for example, has recently been shown to be comparable with PCR and could be performed in less than 30 min by non-laboratory staff, without RNA extractions commonly associated with PCR. Interestingly, NEAR (ID NOW™ COVID-19 (Abbott, IL, USA) was able to detect the virus in 5 min. More so, isothermal platforms are cost effective and could easily be scaled up to resource limited settings. Diagnostics developers, scientific community and commercial companies could consider this alternative method to help stop the spread of COVID-19.
Collapse
Affiliation(s)
- Ameh S. James
- Good Clinical Practice Research Group, School of Veterinary Science, The University of Queensland, Gatton Campus, Gatton, QLD 4343, Australia;
| | | |
Collapse
|
|
166
|
Laboratory diagnosis of SARS-CoV-2 - A review of current methods. J Infect Public Health 2020; 13:901-905. [PMID: 32534946 PMCID: PMC7275982 DOI: 10.1016/j.jiph.2020.06.005] [Citation(s) in RCA: 88] [Impact Index Per Article: 22.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2020] [Revised: 06/01/2020] [Accepted: 06/02/2020] [Indexed: 01/01/2023] Open
Abstract
At present the whole world is facing pandemic of the Coronavirus disease (COVID-19); caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This disease has rapidly spreads across the world from its origin of Wuhan, China and affected millions people worldwide and make them to remain in their homes. The knowledge of available laboratory methods is essential for early and correct diagnosis of COVID-19 to identify new cases as well as monitoring treatment of confirmed cases. In this review we aim to provide the updated information about selection of specimens and availability of various diagnostic methods and their utility with current findings for the laboratory diagnosis of SARS-CoV-2 infection. This will guide the healthcare professionals and government organizations to make strategy for establishing diagnostic facilities for SARS-CoV-2 infections.
Collapse
|
|
167
|
Tabish SA. COVID-19 pandemic: Emerging perspectives and future trends. J Public Health Res 2020; 9:1786. [PMID: 32550223 PMCID: PMC7282311 DOI: 10.4081/jphr.2020.1786] [Citation(s) in RCA: 40] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2020] [Accepted: 05/29/2020] [Indexed: 12/13/2022] Open
Abstract
World is living on the edge. The human cost of COVID pandemic could be extraordinary. We find ourselves in a time of great economic, social, and medical uncertainty. The pandemic demands action on many fronts, from prevention to testing to treatment. We need to create simple, cheap, more accessible testing for SARS-CoV-2. A faster way has to be developed to identify antibodies that neutralize the virus. More than 100 vaccines for the SARS-CoV-2 are at various stages of development. Some six groups have already begun injecting formulations into volunteers in safety trials; others have started testing in animals. The biggest challenge is to determine which vaccine is ideal. Reason and science have to guide us. There is urgent need to critically appraise evidence in deciding how to treat patients. We need a drug or combination of drugs that work. Remdesivir has generated hope. It may prove to be a magic bullet. Countries like Taiwan, Vietnam, Singapore, Hong Kong, South Korea, New Zealand have done exceptionally well to contain the spread of COVID-19. It is widely believed that during the pandemic treatment suffers. Patients with diseases like cancer, diabetes, renal failure, CAD and pregnant women need special attention. As the pandemic pushes up levels of hunger among the global poor, governments must prevent devastating nutrition and health consequences for children missing out on school meals amid school closures. Nations will have endemic SARS-CoV-2 infection for the foreseeable future. A structured and well-coordinated approach is critical for tackling this global crisis. Significance for public health The pattern of infection of COVID-19 is unique and unpredictable. Previous studies have suggested that, similar to SARS-CoV, COVID-19 might interact with the angiotensin-converting enzyme 2 receptor in humans. Virus characteristics primarily define the risk of infection. These characteristics include the efficacy of the virus to spread, the severity of the disease after infection, and the efficacy and success rates of the available medical resources to contain the spread of the virus. With no vaccine or medication, community intervention becomes the most important response strategy against a pandemic. In a world of 7.8 billion people, countries have to be in a state of emergency preparedness to tackle emerging infectious diseases.
Collapse
|
|
168
|
Lau YL, Ismail I, Mustapa NI, Lai MY, Tuan Soh TS, Hassan A, Peariasamy KM, Lee YL, Chong YM, Sam IC, Goh PP. Real-time reverse transcription loop-mediated isothermal amplification for rapid detection of SARS-CoV-2. PeerJ 2020; 8:e9278. [PMID: 32547882 PMCID: PMC7275676 DOI: 10.7717/peerj.9278] [Citation(s) in RCA: 20] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2020] [Accepted: 05/12/2020] [Indexed: 12/17/2022] Open
Abstract
Background Highly sensitive real-time reverse transcription polymerase chain reaction (RT-qPCR) methods have been developed for the detection of SARS-CoV-2. However, they are costly. Loop-mediated isothermal amplification (LAMP) assay has emerged as a novel alternative isothermal amplification method for the detection of nucleic acid. Methods A rapid, sensitive and specific real-time reverse transcription LAMP (RT-LAMP) assay was developed for SARS-CoV-2 detection. Results This assay detected one copy/reaction of SARS-CoV-2 RNA in 30 min. Both the clinical sensitivity and specificity of this assay were 100%. The RT-LAMP showed comparable performance with RT-qPCR. Combining simplicity and cost-effectiveness, this assay is therefore recommended for use in resource resource-limited settings.
Collapse
Affiliation(s)
- Yee Ling Lau
- Department of Parasitology, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia
| | - Ilyiana Ismail
- Department of Pathology, Hospital Sungai Buloh, Selangor, Malaysia
| | | | - Meng Yee Lai
- Department of Parasitology, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia
| | | | - Afifah Hassan
- Department of Pathology, Hospital Sungai Buloh, Selangor, Malaysia
| | | | - Yee Leng Lee
- Clinical Research Centre, Hospital Sungai Buloh, Selangor, Malaysia
| | - Yoong Min Chong
- Department of Medical Microbiology, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia
| | - I-Ching Sam
- Department of Medical Microbiology, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia
| | - Pik Pin Goh
- Institute for Clinical Research (ICR), National Institutes of Health (NIH), Ministry of Health Malaysia, Putrajaya, Malaysia
| |
Collapse
|
|
169
|
Giri AK, Rana DRSJB. Charting the challenges behind the testing of COVID-19 in developing countries: Nepal as a case study. BIOSAFETY AND HEALTH 2020; 2:53-56. [PMID: 38620322 PMCID: PMC7219426 DOI: 10.1016/j.bsheal.2020.05.002] [Citation(s) in RCA: 69] [Impact Index Per Article: 17.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2020] [Revised: 05/06/2020] [Accepted: 05/08/2020] [Indexed: 11/24/2022] Open
Abstract
The infrastructure needed to detect Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection (COVID-19) that complies completely with WHO guidelines is lacking across many parts of the globe, especially in developing countries, including Nepal. We outline the problems faced by such countries and suggest that the national and international community should collaborate in the development and adoption of novel protocols for the rapid detection of COVID-19 according to locally available infrastructure, in order to fight against the outbreak.
Collapse
Affiliation(s)
- Anil K. Giri
- Institute for Molecular Medicine Finland (FIMM), University of Helsinki, FI-00290 Helsinki, Finland
| | | |
Collapse
|
|
170
|
Mollaei HR, Afshar AA, Kalantar-Neyestanaki D, Fazlalipour M, Aflatoonian B. Comparison five primer sets from different genome region of COVID-19 for detection of virus infection by conventional RT-PCR. IRANIAN JOURNAL OF MICROBIOLOGY 2020; 12:185-193. [PMID: 32685113 PMCID: PMC7340604] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
BACKGROUND AND OBJECTIVES The new beta-coronavirus, which caused Severe Acute Respiratory Coronavirus-2 Syndrome (SARS-CoV-2), a major respiratory outbreak in Wuhan, China in December 2019, is now prevalent in many countries around the world. Identifying PCR-based viruses is a well-known and relatively stable protocol. Unfortunately, the high mutation rates may lead to widespread changes in viral nucleic acid sequences, and so using specific primers for PCR can be recommended. In this study, we evaluated the power of a conventional RT-PCR to detect SARS-CoV-2 RNA among the five set primer sets. MATERIALS AND METHODS The five genomic regions of the Coronavirus SARS-2 virus including Nucleocapsids (N), Envelope (E), RNA depended RNA Polymerase (RdRp), ORF1ab and Spike (S) were selected for primer designing. A conventional RT-PCR was performed to compare sensitivity, specificity and other analytical characteristics of primers designed against two Real Time PCR commercial kits. RESULTS The result of the comparative analysis showed that the ORF1ab, N and RdRp primers had a sensitivity, specificity and positive predictive value higher than other primers. A significant difference in the analytical sensitivity between the studied primer sets in RT-PCR kits was observed. CONCLUSION In this study, the ORF1ab, Nucleocapsid and RdRp regions have the best primers for identifying the SARS-CoV-2 RNA between different genes that have been suggested.
Collapse
Affiliation(s)
- Hamid Reza Mollaei
- Tropical and Infectious Diseases Research Center, Kerman University of Medical Sciences, Kerman, Iran,Corresponding author: Hamid Reza Mollaei, Ph.D, Tropical and Infectious Diseases Research Center, Kerman University of Medical Sciences, Kerman, Iran. Telefax: +98-34-33257665,
| | - Abass Aghaei Afshar
- Tropical and Infectious Diseases Research Center, Kerman University of Medical Sciences, Kerman, Iran,Corresponding author: Abass Aghaei Afshar, Ph.D, Tropical and Infectious Diseases Research Center, Kerman University of Medical Sciences, Kerman, Iran. Telefax: +98-34-33257665,
| | | | - Mehdi Fazlalipour
- Department of Arbovirus and Viral Hemorrhagic Fevers (National Ref Lab), Pasteur Institute of Iran (IPI), Tehran, Iran
| | - Behnaz Aflatoonian
- Tropical and Infectious Diseases Research Center, Kerman University of Medical Sciences, Kerman, Iran
| |
Collapse
|
|
171
|
Porte L, Legarraga P, Vollrath V, Aguilera X, Munita JM, Araos R, Pizarro G, Vial P, Iruretagoyena M, Dittrich S, Weitzel T. Evaluation of a novel antigen-based rapid detection test for the diagnosis of SARS-CoV-2 in respiratory samples. Int J Infect Dis 2020; 99:328-333. [PMID: 32497809 PMCID: PMC7263236 DOI: 10.1016/j.ijid.2020.05.098] [Citation(s) in RCA: 233] [Impact Index Per Article: 58.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/23/2020] [Revised: 05/16/2020] [Accepted: 05/24/2020] [Indexed: 12/17/2022] Open
Abstract
Due to the rapidly emerging SARS-CoV-2 pandemic and its tremendous public health challenges worldwide, there is a critical demand for rapid and easy to perform diagnostic assays. The rapid antigen detection test evaluated here had a high diagnostic sensitivity and specificity in respiratory samples obtained from patients who mainly presented during the first week of COVID-19. Rapid antigen detection has the potential to become an important tool for the early diagnosis of SARS-CoV-2, particularly in situations with limited access to molecular methods.
Objectives In the context of the coronavirus disease 2019 (COVID-19) pandemic, the development and validation of rapid and easy-to-perform diagnostic methods are of high priority. This study was performed to evaluate a novel rapid antigen detection test (RDT) for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in respiratory samples. Methods The fluorescence immunochromatographic SARS-CoV-2 antigen test (Bioeasy Biotechnology Co., Shenzhen, China) was evaluated using universal transport medium with nasopharyngeal (NP) and oropharyngeal (OP) swabs from suspected COVID-19 cases. Diagnostic accuracy was determined in comparison to SARS-CoV-2 real-time (RT)-PCR. Results A total of 127 samples were included; 82 were RT-PCR-positive. The median patient age was 38 years, 53.5% were male, and 93.7% were from the first week after symptom onset. Overall sensitivity and specificity were 93.9% (95% confidence interval 86.5–97.4%) and 100% (95% confidence interval 92.1–100%), respectively, with a diagnostic accuracy of 96.1% and Kappa coefficient of 0.9. Sensitivity was significantly higher in samples with high viral loads. Conclusions The RDT evaluated in this study showed a high sensitivity and specificity in samples mainly obtained during the first week of symptoms and with high viral loads, despite the use of a non-validated sample material. The assay has the potential to become an important tool for early diagnosis of SARS-CoV-2, particularly in situations with limited access to molecular methods.
Collapse
Affiliation(s)
- Lorena Porte
- Laboratorio Clínico, Clínica Alemana, Universidad del Desarrollo, Santiago, Chile.
| | - Paulette Legarraga
- Laboratorio Clínico, Clínica Alemana, Universidad del Desarrollo, Santiago, Chile
| | - Valeska Vollrath
- Laboratorio Clínico, Clínica Alemana, Universidad del Desarrollo, Santiago, Chile
| | - Ximena Aguilera
- Centro de Epidemiología y Políticas de Salud, Facultad de Medicina Clínica Alemana, Universidad del Desarrollo, Santiago, Chile
| | - José M Munita
- Servicio de Infectología, Clínica Alemana de Santiago, Facultad de Medicina Clínica Alemana, Universidad del Desarrollo, Santiago, Chile; Instituto de Ciencias e Innovación en Medicina (ICIM), Facultad de Medicina Clínica Alemana, Universidad del Desarrollo, Santiago, Chile; Millennium Initiative for Collaborative Research On Bacterial Resistance (MICROB-R), Santiago, Chile
| | - Rafael Araos
- Servicio de Infectología, Clínica Alemana de Santiago, Facultad de Medicina Clínica Alemana, Universidad del Desarrollo, Santiago, Chile; Instituto de Ciencias e Innovación en Medicina (ICIM), Facultad de Medicina Clínica Alemana, Universidad del Desarrollo, Santiago, Chile; Millennium Initiative for Collaborative Research On Bacterial Resistance (MICROB-R), Santiago, Chile
| | - Gabriel Pizarro
- Laboratorio Clínico, Clínica Alemana, Universidad del Desarrollo, Santiago, Chile
| | - Pablo Vial
- Instituto de Ciencias e Innovación en Medicina (ICIM), Facultad de Medicina Clínica Alemana, Universidad del Desarrollo, Santiago, Chile
| | | | - Sabine Dittrich
- Foundation for Innovative New Diagnostics (FIND), Malaria and Fever Program, Geneva, Switzerland; Nuffield Department of Medicine, University of Oxford, Oxford, UK
| | - Thomas Weitzel
- Laboratorio Clínico, Clínica Alemana, Universidad del Desarrollo, Santiago, Chile; Instituto de Ciencias e Innovación en Medicina (ICIM), Facultad de Medicina Clínica Alemana, Universidad del Desarrollo, Santiago, Chile.
| |
Collapse
|
|
172
|
Younes N, Al-Sadeq DW, AL-Jighefee H, Younes S, Al-Jamal O, Daas HI, Yassine HM, Nasrallah GK. Challenges in Laboratory Diagnosis of the Novel Coronavirus SARS-CoV-2. Viruses 2020; 12:E582. [PMID: 32466458 PMCID: PMC7354519 DOI: 10.3390/v12060582] [Citation(s) in RCA: 248] [Impact Index Per Article: 62.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2020] [Revised: 05/19/2020] [Accepted: 05/20/2020] [Indexed: 12/13/2022] Open
Abstract
The recent outbreak of the Coronavirus disease 2019 (COVID-19) has quickly spread worldwide since its discovery in Wuhan city, China in December 2019. A comprehensive strategy, including surveillance, diagnostics, research, clinical treatment, and development of vaccines, is urgently needed to win the battle against COVID-19. The past three unprecedented outbreaks of emerging human coronavirus infections at the beginning of the 21st century have highlighted the importance of readily available, accurate, and rapid diagnostic technologies to contain emerging and re-emerging pandemics. Real-time reverse transcriptase-polymerase chain reaction (rRT-PCR) based assays performed on respiratory specimens remain the gold standard for COVID-19 diagnostics. However, point-of-care technologies and serologic immunoassays are rapidly emerging with high sensitivity and specificity as well. Even though excellent techniques are available for the diagnosis of symptomatic patients with COVID-19 in well-equipped laboratories; critical gaps still remain in screening asymptomatic people who are in the incubation phase of the virus, as well as in the accurate determination of live viral shedding during convalescence to inform decisions for ending isolation. This review article aims to discuss the currently available laboratory methods and surveillance technologies available for the detection of COVID-19, their performance characteristics and highlight the gaps in current diagnostic capacity, and finally, propose potential solutions. We also summarize the specifications of the majority of the available commercial kits (PCR, EIA, and POC) for laboratory diagnosis of COVID-19.
Collapse
Affiliation(s)
- Nadin Younes
- Biomedical Research Center, Qatar University, P.O. Box 2713 Doha, Qatar; (N.Y.); (D.W.A.-S.); (H.A.-J.); (O.A.-J.); (H.M.Y.)
| | - Duaa W. Al-Sadeq
- Biomedical Research Center, Qatar University, P.O. Box 2713 Doha, Qatar; (N.Y.); (D.W.A.-S.); (H.A.-J.); (O.A.-J.); (H.M.Y.)
- College of Medicine, Member of QU Health, Qatar University, P.O. Box 2713 Doha, Qatar
| | - Hadeel AL-Jighefee
- Biomedical Research Center, Qatar University, P.O. Box 2713 Doha, Qatar; (N.Y.); (D.W.A.-S.); (H.A.-J.); (O.A.-J.); (H.M.Y.)
| | - Salma Younes
- Department of Biomedical Science, College of Health Sciences, Member of QU Health, Qatar University, P.O. Box 2713 Doha, Qatar;
| | - Ola Al-Jamal
- Biomedical Research Center, Qatar University, P.O. Box 2713 Doha, Qatar; (N.Y.); (D.W.A.-S.); (H.A.-J.); (O.A.-J.); (H.M.Y.)
| | - Hanin I. Daas
- College of Dental Medicine, Member of QU Health, Qatar University, P.O. Box 2713 Doha, Qatar;
| | - Hadi. M. Yassine
- Biomedical Research Center, Qatar University, P.O. Box 2713 Doha, Qatar; (N.Y.); (D.W.A.-S.); (H.A.-J.); (O.A.-J.); (H.M.Y.)
- Department of Biomedical Science, College of Health Sciences, Member of QU Health, Qatar University, P.O. Box 2713 Doha, Qatar;
| | - Gheyath K. Nasrallah
- Biomedical Research Center, Qatar University, P.O. Box 2713 Doha, Qatar; (N.Y.); (D.W.A.-S.); (H.A.-J.); (O.A.-J.); (H.M.Y.)
- Department of Biomedical Science, College of Health Sciences, Member of QU Health, Qatar University, P.O. Box 2713 Doha, Qatar;
| |
Collapse
|
|
173
|
Chen L, Upadhya G, Guo US, Belligund P, Lee DK, Shalom I, Dubey GR, Al-Ajam MR, Mitre CA. Novel Coronavirus-Induced Right Ventricular Failure and Point of Care Echocardiography: A Case Report. Cardiology 2020; 145:467-472. [PMID: 32450565 PMCID: PMC7316647 DOI: 10.1159/000508527] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/08/2020] [Accepted: 04/09/2020] [Indexed: 01/19/2023]
Abstract
Various cardiovascular complications have been reported in patients with coronavirus disease 2019. Common complications include acute myocardial injury, myocarditis, arrhythmia, pericarditis, heart failure, and shock. We present a case of cor pulmonale diagnosed with serial point of care ultrasound. Given the current shortage of personal protective equipment (PPE) and high infectivity of this virus, we acknowledge the utility of this tool in obtaining important clinical information while minimizing exposure and PPE consumption.
Collapse
Affiliation(s)
- Lu Chen
- Department of Internal Medicine, Downstate Medical Center, State University of New York, Brooklyn, New York, USA
- Division of Cardiology, Department of Internal Medicine, Brooklyn Campus, Veterans Affairs New York Harbor Healthcare System, Brooklyn, New York, USA
| | - Gautham Upadhya
- Division of Cardiology, Department of Internal Medicine, Downstate Medical Center, State University of New York, Brooklyn, New York, USA
| | - Uta S Guo
- Sunrise Health Consortium, Southern Hills Hospital Family Medicine GME, Las Vegas, Nevada, USA
| | - Pooja Belligund
- Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Brooklyn Campus, Veterans Affairs New York Harbor Healthcare System, Brooklyn, New York, USA
| | - David K Lee
- Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Brooklyn Campus, Veterans Affairs New York Harbor Healthcare System, Brooklyn, New York, USA
| | - Isaac Shalom
- Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Brooklyn Campus, Veterans Affairs New York Harbor Healthcare System, Brooklyn, New York, USA
| | - Gangacharan R Dubey
- Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Brooklyn Campus, Veterans Affairs New York Harbor Healthcare System, Brooklyn, New York, USA
| | - Mohammad R Al-Ajam
- Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Brooklyn Campus, Veterans Affairs New York Harbor Healthcare System, Brooklyn, New York, USA
| | - Cristina A Mitre
- Division of Cardiology, Department of Internal Medicine, Brooklyn Campus, Veterans Affairs New York Harbor Healthcare System, Brooklyn, New York, USA,
| |
Collapse
|
|
174
|
Eggleton EJ. Simple, fast and affordable triaging pathway for COVID-19. Postgrad Med J 2020; 97:192-195. [PMID: 32439731 DOI: 10.1136/postgradmedj-2020-138029] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2020] [Accepted: 05/10/2020] [Indexed: 12/15/2022]
Abstract
Coronavirus disease 2019 has caused a global pandemic. The majority of patients will experience mild disease, but others will develop a severe respiratory infection that requires hospitalisation. This is causing a significant strain on health services. Patients are presenting at emergency departments with symptoms of dyspnoea, dry cough and fever with varying severity. The appropriate triaging of patients will assist in preventing health services becoming overwhelmed during the pandemic. This is assisted through clinical assessment and various imaging and laboratory investigations, including chest X-ray, blood analysis and identification of viral infection with SARS-CoV-2. Here, a succinct triaging pathway that aims to be fast, reliable and affordable is presented. The hope is that such a pathway will assist health services in appropriately combating the pandemic.
Collapse
Affiliation(s)
- Elizabeth Jane Eggleton
- Cardiology Department, Addenbrooke's Hospital, Cambridge University Hospitals, Cambridge, UK .,Medical School, The University of Newcastle, Newcastle upon Tyne, UK
| |
Collapse
|
|
175
|
Covid-19: Open-Data Resources for Monitoring, Modeling, and Forecasting the Epidemic. ELECTRONICS 2020. [DOI: 10.3390/electronics9050827] [Citation(s) in RCA: 45] [Impact Index Per Article: 11.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
We provide an insight into the open-data resources pertinent to the study of the spread of the Covid-19 pandemic and its control. We identify the variables required to analyze fundamental aspects like seasonal behavior, regional mortality rates, and effectiveness of government measures. Open-data resources, along with data-driven methodologies, provide many opportunities to improve the response of the different administrations to the virus. We describe the present limitations and difficulties encountered in most of the open-data resources. To facilitate the access to the main open-data portals and resources, we identify the most relevant institutions, on a global scale, providing Covid-19 information and/or auxiliary variables (demographics, mobility, etc.). We also describe several open resources to access Covid-19 datasets at a country-wide level (i.e., China, Italy, Spain, France, Germany, US, etc.). To facilitate the rapid response to the study of the seasonal behavior of Covid-19, we enumerate the main open resources in terms of weather and climate variables. We also assess the reusability of some representative open-data sources.
Collapse
|
|
176
|
Wang J, Cai K, He X, Shen X, Wang J, Liu J, Xu J, Qiu F, Lei W, Cui L, Ge Y, Wu T, Zhang Y, Yan H, Chen Y, Yu J, Ma X, Shi H, Zhang R, Li X, Gao Y, Niu P, Tan W, Wu G, Jiang Y, Xu W, Ma X. Multiple-centre clinical evaluation of an ultrafast single-tube assay for SARS-CoV-2 RNA. Clin Microbiol Infect 2020; 26:1076-1081. [PMID: 32422410 PMCID: PMC7227500 DOI: 10.1016/j.cmi.2020.05.007] [Citation(s) in RCA: 32] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2020] [Revised: 05/06/2020] [Accepted: 05/07/2020] [Indexed: 12/13/2022]
Abstract
OBJECTIVE To evaluate the performance of an ultrafast single-tube nucleic acid isothermal amplification detection assay for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA using clinical samples from multiple centres. METHODS A reverse transcription recombinase-aided amplification (RT-RAA) assay for SARS-CoV-2 was conducted within 15 minutes at 39°C with portable instruments after addition of extracted RNA. The clinical performance of RT-RAA assay was evaluated using 947 clinical samples from five institutions in four regions of China; approved commercial fluorescence quantitative real-time PCR (qRT-PCR) kits were used for parallel detection. The sensitivity and specificity of RT-RAA were compared and analysed. RESULTS The RT-RAA test results of 926 samples were consistent with those of qRT-PCR (330 were positive, 596 negative); 21 results were inconsistent. The sensitivity and specificity of RT-RAA was 97.63% (330/338, 95% confidence interval (CI) 95.21 to 98.90) and 97.87% (596/609, 95% CI 96.28 to 98.81) respectively. The positive and negative predictive values were 96.21% (330/343, 95% CI 93.45 to 97.88) and 98.68% (596/604, 95% CI 97.30 to 99.38) respectively. The total coincidence rate was 97.78% (926/947, 95% CI 96.80 to 98.70), and the kappa was 0.952 (p < 0.05). CONCLUSIONS With comparable sensitivity and specificity to the commercial qRT-PCR kits, RT-RAA assay for SARS-CoV-2 exhibited the distinctive advantages of simplicity and rapidity in terms of operation and turnaround time.
Collapse
Affiliation(s)
- J Wang
- National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China
| | - K Cai
- Hubei Center for Disease Control and Prevention, Wuhan 430000, China
| | - X He
- National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China
| | - X Shen
- National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China
| | - J Wang
- National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China; Hebei Medical University, Shijiazhuang 050031, China
| | - J Liu
- National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China
| | - J Xu
- Hubei Center for Disease Control and Prevention, Wuhan 430000, China
| | - F Qiu
- National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China
| | - W Lei
- National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China
| | - L Cui
- NHC Key Laboratories of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, 210009, China
| | - Y Ge
- NHC Key Laboratories of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, 210009, China
| | - T Wu
- NHC Key Laboratories of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, 210009, China
| | - Y Zhang
- Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou 310000, China
| | - H Yan
- Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou 310000, China
| | - Y Chen
- Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou 310000, China
| | - J Yu
- The NO.1 Affiliated hospital of Shanxi Datong University, Institute of Brain Science-Shanxi Key Laboratory of Inflammatory Neurodegenerative Diseases, Datong 037000, China
| | - X Ma
- The NO.1 Affiliated hospital of Shanxi Datong University, Institute of Brain Science-Shanxi Key Laboratory of Inflammatory Neurodegenerative Diseases, Datong 037000, China; The Fifth People's Hospital of DaTong, Datong 037000, China
| | - H Shi
- Datong City Center for Disease Control and Prevention, Datong 037000, China
| | - R Zhang
- National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China; Hebei Medical University, Shijiazhuang 050031, China
| | - X Li
- National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China
| | - Y Gao
- National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China; Hebei Medical University, Shijiazhuang 050031, China
| | - P Niu
- National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China
| | - W Tan
- National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China
| | - G Wu
- National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China
| | - Y Jiang
- Hubei Center for Disease Control and Prevention, Wuhan 430000, China.
| | - W Xu
- National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China.
| | - X Ma
- National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China; Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan 430071, China.
| |
Collapse
|
|
177
|
Sarvepalli D. Coronavirus Disease 2019: A Comprehensive Review of Etiology, Pathogenesis, Diagnosis, and Ongoing Clinical Trials. Cureus 2020; 12:e8076. [PMID: 32542131 PMCID: PMC7292713 DOI: 10.7759/cureus.8076] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2020] [Accepted: 05/12/2020] [Indexed: 01/15/2023] Open
Abstract
Coronavirus disease 2019 (COVID-19) is an acute respiratory viral infection caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The disease outbreak started in China in late December 2019 and quickly spread to the rest of the world, resulting in a pandemic. The incidence of cases is increasing every day, affecting millions of people around the globe and resulting in a public health emergency. Furthermore, disease management has been challenging for the clinicians and other medical personnel in terms of treatment options and availability of personal protective equipment. The off-label use of drugs such as hydroxychloroquine and emergency use authorization of remdesivir can hopefully help the clinicians while treating critically ill patients. The use of convalescent serum has also shown some interim benefit until a definitive treatment and preventive options are uncovered, such as vaccines and other effective treatment regimens.
Collapse
|
|
178
|
Chanda-Kapata P, Kapata N, Zumla A. COVID-19 and malaria: A symptom screening challenge for malaria endemic countries. Int J Infect Dis 2020; 94:151-153. [PMID: 32344326 PMCID: PMC7184246 DOI: 10.1016/j.ijid.2020.04.007] [Citation(s) in RCA: 51] [Impact Index Per Article: 12.8] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2020] [Accepted: 04/02/2020] [Indexed: 12/15/2022] Open
Affiliation(s)
| | - Nathan Kapata
- Zambia National Public Health Institute, Ministry of Health, Lusaka, Zambia.
| | - Alimuddin Zumla
- Department of Infection, Division of Infection and Immunity, University College London and NIHR Biomedical Research Centre, UCL Hospitals NHS Foundation Trust, London, United Kingdom.
| |
Collapse
|
|
179
|
Fiorillo L, Cervino G, Matarese M, D’Amico C, Surace G, Paduano V, Fiorillo MT, Moschella A, La Bruna A, Romano GL, Laudicella R, Baldari S, Cicciù M. COVID-19 Surface Persistence: A Recent Data Summary and Its Importance for Medical and Dental Settings. INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH 2020; 17:E3132. [PMID: 32365891 PMCID: PMC7246498 DOI: 10.3390/ijerph17093132] [Citation(s) in RCA: 108] [Impact Index Per Article: 27.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 04/14/2020] [Revised: 04/27/2020] [Accepted: 04/28/2020] [Indexed: 12/18/2022]
Abstract
Recently, due to the coronavirus pandemic, many guidelines and anti-contagion strategies continue to report unclear information about the persistence of coronavirus disease 2019 (COVID-19) in the environment. This certainly generates insecurity and fear in people, with an important psychological component that is not to be underestimated at this stage of the pandemic. The purpose of this article is to highlight all the sources currently present in the literature concerning the persistence of the different coronaviruses in the environment as well as in medical and dental settings. As this was a current study, there are still not many sources in the literature, and scientific strategies are moving towards therapy and diagnosis, rather than knowing the characteristics of the virus. Such an article could be an aid to summarize virus features and formulate new guidelines and anti-spread strategies.
Collapse
Affiliation(s)
- Luca Fiorillo
- Department of Biomedical and Dental Sciences, Morphological and Functional Images, University of Messina, Azienda Ospedaliera Universitaria “G. Martino”, Via Consolare Valeria, 98100 Messina, Italy; (G.C.); (M.M.); (C.D.); (S.B.)
| | - Gabriele Cervino
- Department of Biomedical and Dental Sciences, Morphological and Functional Images, University of Messina, Azienda Ospedaliera Universitaria “G. Martino”, Via Consolare Valeria, 98100 Messina, Italy; (G.C.); (M.M.); (C.D.); (S.B.)
| | - Marco Matarese
- Department of Biomedical and Dental Sciences, Morphological and Functional Images, University of Messina, Azienda Ospedaliera Universitaria “G. Martino”, Via Consolare Valeria, 98100 Messina, Italy; (G.C.); (M.M.); (C.D.); (S.B.)
| | - Cesare D’Amico
- Department of Biomedical and Dental Sciences, Morphological and Functional Images, University of Messina, Azienda Ospedaliera Universitaria “G. Martino”, Via Consolare Valeria, 98100 Messina, Italy; (G.C.); (M.M.); (C.D.); (S.B.)
| | - Giovanni Surace
- Clinical Analysis Laboratory “Dott. Francesco Siracusa Rizzi s.r.l.”, Via Nazionale Archi, 89121 Reggio Calabria, RC, Italy;
- Unit of Microbiology and Virology, North Health Center ASP 5, 89100 Reggio Calabria, RC, Italy; (V.P.); (M.T.F.)
| | - Valeria Paduano
- Unit of Microbiology and Virology, North Health Center ASP 5, 89100 Reggio Calabria, RC, Italy; (V.P.); (M.T.F.)
| | - Maria Teresa Fiorillo
- Unit of Microbiology and Virology, North Health Center ASP 5, 89100 Reggio Calabria, RC, Italy; (V.P.); (M.T.F.)
| | - Antonio Moschella
- Azienda Ospedaliera Bianchi-Melacrino-Morelli, 89100 Reggio Calabria, RC, Italy;
| | | | - Giovanni Luca Romano
- Department of Biomedical and Biotechnological Sciences, School of Medicine, University of Catania, 95100 Catania, Italy;
| | - Riccardo Laudicella
- Nuclear Medicine Unit, Department of Biomedical and Dental Sciences and Morpho-Functional Imaging, University of Messina, 98100 Messina, Italy;
| | - Sergio Baldari
- Department of Biomedical and Dental Sciences, Morphological and Functional Images, University of Messina, Azienda Ospedaliera Universitaria “G. Martino”, Via Consolare Valeria, 98100 Messina, Italy; (G.C.); (M.M.); (C.D.); (S.B.)
- Nuclear Medicine Unit, Department of Biomedical and Dental Sciences and Morpho-Functional Imaging, University of Messina, 98100 Messina, Italy;
| | - Marco Cicciù
- Department of Biomedical and Dental Sciences, Morphological and Functional Images, University of Messina, Azienda Ospedaliera Universitaria “G. Martino”, Via Consolare Valeria, 98100 Messina, Italy; (G.C.); (M.M.); (C.D.); (S.B.)
| |
Collapse
|
|
180
|
Bachelet VC. Do we know the diagnostic properties of the tests used in COVID-19? A rapid review of recently published literature. Medwave 2020; 20:e7890. [PMID: 32353857 DOI: 10.5867/medwave.2020.03.7891] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2020] [Accepted: 04/26/2020] [Indexed: 11/27/2022] Open
Abstract
COVID-19 has brought death and disease to large parts of the world. Governments must deploy strategies to screen the population and subsequently isolate the suspect cases. Diagnostic testing is critical for epidemiological surveillance, but the accuracy (sensitivity and specificity) and clinical utility (impact on health outcomes) of the current diagnostic methods used for SARS-CoV-2 detection are not known. I ran a quick search in PubMed/MEDLINE to find studies on laboratory diagnostic tests and rapid viral diagnosis. After running the search strategies, I found 47 eligible articles that I discuss in this review, commenting on test characteristics and limitations. I did not find any papers that report on the clinical utility of the tests currently used for COVID-19 detection, meaning that we are fighting a battle without proper knowledge of the proportion of false negatives that current testing is resulting in. This shortcoming should not be overlooked as it might hamper national efforts to contain the pandemic through testing community-based suspect cases.
Collapse
Affiliation(s)
- Vivienne C Bachelet
- Escuela de Medicina, Facultad de Ciencias Médicas, Universidad de Santiago de Chile (USACH), Santiago, Chile. . ORCID: 0000-0002-5715-9755
| |
Collapse
|
|
181
|
Kashir J, Yaqinuddin A. Loop mediated isothermal amplification (LAMP) assays as a rapid diagnostic for COVID-19. Med Hypotheses 2020; 141:109786. [PMID: 32361529 PMCID: PMC7182526 DOI: 10.1016/j.mehy.2020.109786] [Citation(s) in RCA: 164] [Impact Index Per Article: 41.0] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2020] [Accepted: 04/23/2020] [Indexed: 01/11/2023]
Abstract
Recently, a novel coronavirus (SARS-CoV-2; coronavirus disease 2019, COVID-19) has emerged, rapidly spreading and severely straining the capacity of the global health community. Many nations are employing combinations of containment and mitigation strategies, where early diagnosis of COVID-19 is vital in controlling illness progression and limiting viral spread within the population. Thus, rapid and accurate methods of early detection are vital to contain COVID-19 and prevent further spread and predicted subsequent infectious waves of viral recurrence in future. Immediately after its initial characterization, Chinese and American Centers for Disease Control and Prevention (CDCs) rapidly employed molecular assays for detection of COVID-19, mostly employing real-time polymerase chain reaction (RT-PCR) methods. However, such methods require specific expensive items of equipment and highly trained analysts, requiring upwards of 4–8 h to process. These requirements coupled with associated financial pressures may prevent effective deployment of such diagnostic tests. Loop mediated isothermal amplification (LAMP) is method of nucleic acid amplification which exhibits increased sensitivity and specificity are significantly rapid, and do not require expensive reagents or instruments, which aids in cost reduction for coronavirus detection. Studies have shown the successful application of LAMP assays in various forms to detect coronavirus RNA in patient samples, demonstrating that 1–10 copies of viral RNA template per reaction are sufficient for successful detection, ~100-fold more sensitive than conventional RT-PCR methods. Importantly, studies have also now demonstrated the effectiveness of LAMP methodology in the detection of SARS-CoV-2 RNA at significantly low levels, particularly following numerous improvements to LAMP assay protocols. We hypothesise that recent advancements in enhanced LAMP protocols assay perhaps represent the best chance for a rapid and robust assay for field diagnosis of COVID-19, without the requirement of specialized equipment and highly trained professionals to interpret results. Herein, we present our arguments with a view to disseminate such findings, to assist the combat of this virus that is proving so devastating. We hope that this strategy could be applied rapidly, and confirmed for viability with clinical samples, before being rolled out for mass-diagnostic testing in these current times.
Collapse
Affiliation(s)
- Junaid Kashir
- College of Medicine, Alfaisal University, Riyadh, Saudi Arabia; Department of Comparative Medicine, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.
| | | |
Collapse
|
|
182
|
Mboowa G. Current and emerging diagnostic tests available for the novel COVID-19 global pandemic. AAS Open Res 2020; 3:8. [PMID: 32537561 PMCID: PMC7255909 DOI: 10.12688/aasopenres.13059.1] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/15/2020] [Indexed: 02/01/2023] Open
Abstract
On March 11, 2020 the World Health Organization (WHO) upgraded the status of the coronavirus disease 2019 (COVID-19) outbreak from epidemic to a global pandemic. This infection is caused by a novel coronavirus, SARS-CoV-2. Several rapid diagnostic tests have been developed at an astonishing pace; however, COVID-19 requires more highly specific rapid point-of-care diagnostic tests. This review describes the currently available testing approaches, as well as the available test assays including the Xpert® Xpress SARS-CoV-2 test (takes
~45 min) and Abbott ID COVID-19 test (5 min) as easy to use point-of-care tests for diagnosis of novel COVID-19 that have so far received the US Food and Drug Administration emergency use authorizations clearance. This review is correct as of the date published and will be updated as more diagnostic tests come to light.
Collapse
Affiliation(s)
- Gerald Mboowa
- The African Center of Excellence in Bioinformatics and Data-Intensive Sciences, The Infectious Disease Institute, Makerere University, Kampala, Uganda.,Department of Immunology and Molecular Biology, College of Health Sciences, Makerere University, Kampala, Uganda
| |
Collapse
|
|
183
|
Nadeem MS, Zamzami MA, Choudhry H, Murtaza BN, Kazmi I, Ahmad H, Shakoori AR. Origin, Potential Therapeutic Targets and Treatment for Coronavirus Disease (COVID-19). Pathogens 2020; 9:E307. [PMID: 32331255 PMCID: PMC7238035 DOI: 10.3390/pathogens9040307] [Citation(s) in RCA: 42] [Impact Index Per Article: 10.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2020] [Revised: 04/16/2020] [Accepted: 04/19/2020] [Indexed: 01/08/2023] Open
Abstract
The ongoing episode of coronavirus disease 19 (COVID-19) has imposed a serious threat to global health and the world economy. The disease has rapidly acquired a pandemic status affecting almost all populated areas of the planet. The causative agent of COVID-19 is a novel coronavirus known as SARS-CoV-2. The virus has an approximate 30 kb single-stranded positive-sense RNA genome, which is 74.5% to 99% identical to that of SARS-CoV, CoV-pangolin, and the coronavirus the from horseshoe bat. According to available information, SARS-CoV-2 is inferred to be a recombinant virus that originated from bats and was transmitted to humans, possibly using the pangolin as the intermediate host. The interaction of the SARS-CoV-2 spike protein with the human ACE2 (angiotensin-converting enzyme 2) receptor, and its subsequent cleavage by serine protease and fusion, are the main events in the pathophysiology. The serine protease inhibitors, spike protein-based vaccines, or ACE2 blockers may have therapeutic potential in the near future. At present, no vaccine is available against COVID-19. The disease is being treated with antiviral, antimalarial, anti-inflammatory, herbal medicines, and active plasma antibodies. In this context, the present review article provides a cumulative account of the recent information regarding the viral characteristics, potential therapeutic targets, treatment options, and prospective research questions.
Collapse
Affiliation(s)
- Muhammad Shahid Nadeem
- Department of Biochemistry, Faculty of Science, King Abdulaziz University, Jeddah 21589, Saudi Arabia; (M.A.Z.); (H.C.); (I.K.)
| | - Mazin A. Zamzami
- Department of Biochemistry, Faculty of Science, King Abdulaziz University, Jeddah 21589, Saudi Arabia; (M.A.Z.); (H.C.); (I.K.)
| | - Hani Choudhry
- Department of Biochemistry, Faculty of Science, King Abdulaziz University, Jeddah 21589, Saudi Arabia; (M.A.Z.); (H.C.); (I.K.)
| | - Bibi Nazia Murtaza
- Department of Microbiology, Abbottabad University of Science and Technology, Abbottabad 22010, Pakistan;
| | - Imran Kazmi
- Department of Biochemistry, Faculty of Science, King Abdulaziz University, Jeddah 21589, Saudi Arabia; (M.A.Z.); (H.C.); (I.K.)
| | - Habib Ahmad
- Department of Genetics, Hazara University Garden Campus, Mansehra 21300, Pakistan;
| | - Abdul Rauf Shakoori
- School of Biological Sciences, University of the Punjab, Lahore 54000, Pakistan;
| |
Collapse
|
|
184
|
COVID-19 in otolaryngologist practice: a review of current knowledge. Eur Arch Otorhinolaryngol 2020; 277:1885-1897. [PMID: 32306118 PMCID: PMC7166003 DOI: 10.1007/s00405-020-05968-y] [Citation(s) in RCA: 116] [Impact Index Per Article: 29.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2020] [Accepted: 04/06/2020] [Indexed: 02/06/2023]
Abstract
Purpose Otorhinolaryngological manifestations are common symptoms of COVID-19. This study provides a brief and precise review of the current knowledge regarding COVID-19, including disease transmission, clinical characteristics, diagnosis, and potential treatment. The article focused on COVID-19-related information useful in otolaryngologist practice. Methods The Medline and Web of Science databases were searched without a time limit using terms “COVID-19”, “SARS-CoV-2” in conjunction with “otorhinolaryngological manifestation”, “ENT”, and “olfaction”. Results The most common otolaryngological dysfunctions of COVID-19 were cough, sore throat, and dyspnea. Rhinorrhea, nasal congestion and dizziness were also present. COVID-19 could manifest as an isolated sudden hyposmia/anosmia. Upper respiratory tract (URT) symptoms were commonly observed in younger patients and usually appeared initially. They could be present even before the molecular confirmation of SARS-CoV-2. Otolaryngologists are of great risk of becoming infected with SARS-CoV-2 as they cope with URT. ENT surgeons could be easily infected by SARS-CoV-2 during performing surgery in COVID-19 patients. Conclusion Ear, nose and throat (ENT) symptoms may precede the development of severe COVID-19. During COVID-19 pandemic, patients with cough, sore throat, dyspnea, hyposmia/anosmia and a history of travel to the region with confirmed COVID-19 patients, should be considered as potential COVID-19 cases. An otolaryngologist should wear FFP3/N95 mask, glasses, disposable and fluid resistant gloves and gown while examining such individuals. Not urgent ENT surgeries should be postponed. Additional studies analyzing why some patients develop ENT symptoms during COVID-19 and others do not are needed. Further research is needed to determine the mechanism leading to anosmia.
Collapse
|
|
185
|
Amawi H, Abu Deiab GI, A Aljabali AA, Dua K, Tambuwala MM. COVID-19 pandemic: an overview of epidemiology, pathogenesis, diagnostics and potential vaccines and therapeutics. Ther Deliv 2020; 11:245-268. [PMID: 32397911 PMCID: PMC7222554 DOI: 10.4155/tde-2020-0035] [Citation(s) in RCA: 89] [Impact Index Per Article: 22.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2020] [Accepted: 04/22/2020] [Indexed: 02/07/2023] Open
Abstract
At the time of writing this review, severe acute respiratory coronavirus syndrome-2 (SARS-CoV-2) has infected more than 2,355,853 patients and resulted in more than 164,656 deaths worldwide (as of 20 April 2020). This review highlights the preventive measures, available clinical therapies and the potential of vaccine development against SARS-CoV-2 by taking into consideration the strong genetic similarities of the 2003 epidemic SARS-CoV. Recent studies are investigating the repurposing of US FDA-approved drugs as there is no available vaccine yet with many attempts under clinical evaluation. Several antivirals, antimalarials and immunomodulators that have shown activity against SARS-CoV and Middle East coronavirus respiratory syndromes are being evaluated. In particular, hydroxychloroquine, remdesivir, favipiravir, arbidol, tocilizumab and bevacizumab have shown promising results. The main aim of this review is to provide an overview of this pandemic and where we currently stand.
Collapse
Affiliation(s)
- Haneen Amawi
- Faculty of Pharmacy, Department of Pharmacy Practice, Yarmouk University, Irbid-Jordan
| | - Ghina'a I Abu Deiab
- Faculty of Pharmacy, Department of Medicinal Chemistry & Pharmacognosy, Yarmouk University, Irbid-Jordan
| | - Alaa A A Aljabali
- Faculty of Pharmacy, Department of Pharmaceutics & Pharmaceutical Technology, Yarmouk University, Irbid-Jordan
| | - Kamal Dua
- Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Ultimo, NSW 2007, Australia
| | - Murtaza M Tambuwala
- School of Pharmacy & Pharmaceutical Sciences, Ulster University, Coleraine, County Londonderry, BT52 1SA, Northern Ireland, UK
| |
Collapse
|
|
186
|
Abstract
Die Corona-Krise trifft aktuell sowohl unsere Patienten als auch die geriatrischen Strukturen in allen Sektoren. Mit unserem aktuellen Beitrag geben wir Ihnen einen Überblick über den aktuellen Kenntnisstand von COVID-19 mit besonderer Berücksichtigung geriatrischer Aspekte, sowohl im Hinblick auf den medizinischen Bereich als auch auf die geriatrischen Strukturen.
Collapse
|
|
187
|
|
|
188
|
Poghossian A, Jablonski M, Molinnus D, Wege C, Schöning MJ. Field-Effect Sensors for Virus Detection: From Ebola to SARS-CoV-2 and Plant Viral Enhancers. FRONTIERS IN PLANT SCIENCE 2020; 11:598103. [PMID: 33329662 PMCID: PMC7732584 DOI: 10.3389/fpls.2020.598103] [Citation(s) in RCA: 20] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/23/2020] [Accepted: 10/26/2020] [Indexed: 05/06/2023]
Abstract
Coronavirus disease 2019 (COVID-19) is a novel human infectious disease provoked by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Currently, no specific vaccines or drugs against COVID-19 are available. Therefore, early diagnosis and treatment are essential in order to slow the virus spread and to contain the disease outbreak. Hence, new diagnostic tests and devices for virus detection in clinical samples that are faster, more accurate and reliable, easier and cost-efficient than existing ones are needed. Due to the small sizes, fast response time, label-free operation without the need for expensive and time-consuming labeling steps, the possibility of real-time and multiplexed measurements, robustness and portability (point-of-care and on-site testing), biosensors based on semiconductor field-effect devices (FEDs) are one of the most attractive platforms for an electrical detection of charged biomolecules and bioparticles by their intrinsic charge. In this review, recent advances and key developments in the field of label-free detection of viruses (including plant viruses) with various types of FEDs are presented. In recent years, however, certain plant viruses have also attracted additional interest for biosensor layouts: Their repetitive protein subunits arranged at nanometric spacing can be employed for coupling functional molecules. If used as adapters on sensor chip surfaces, they allow an efficient immobilization of analyte-specific recognition and detector elements such as antibodies and enzymes at highest surface densities. The display on plant viral bionanoparticles may also lead to long-time stabilization of sensor molecules upon repeated uses and has the potential to increase sensor performance substantially, compared to conventional layouts. This has been demonstrated in different proof-of-concept biosensor devices. Therefore, richly available plant viral particles, non-pathogenic for animals or humans, might gain novel importance if applied in receptor layers of FEDs. These perspectives are explained and discussed with regard to future detection strategies for COVID-19 and related viral diseases.
Collapse
Affiliation(s)
| | - Melanie Jablonski
- Institute of Nano- and Biotechnologies, FH Aachen University of Applied Sciences, Jülich, Germany
- Institute of Pharmaceutical Chemistry, Philipps-University Marburg, Marburg, Germany
| | - Denise Molinnus
- Institute of Nano- and Biotechnologies, FH Aachen University of Applied Sciences, Jülich, Germany
| | - Christina Wege
- Institute of Biomaterials and Biomolecular Systems, University of Stuttgart, Stuttgart, Germany
- *Correspondence: Christina Wege,
| | - Michael J. Schöning
- Institute of Nano- and Biotechnologies, FH Aachen University of Applied Sciences, Jülich, Germany
- Institute of Complex Systems (ICS-8), Research Centre Jülich GmbH, Jülich, Germany
- Michael J. Schöning,
| |
Collapse
|
|
189
|
Ahmad S, Ali N, Kausar M, Misbah H, Wahid A. Road toward rapid-molecular point of care test to detect novel SARS-coronavirus 2019 (COVID-19): Review from updated literature. Allergol Immunopathol (Madr) 2020; 48:518-520. [PMID: 32636083 PMCID: PMC7328543 DOI: 10.1016/j.aller.2020.06.001] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2020] [Accepted: 06/20/2020] [Indexed: 11/30/2022]
Abstract
Coronavirus disease 2019 (COVID-19) named by the WHO as a result of the global public health emergency. COVID-19 is caused by a new coronavirus named as novel coronavirus (2019-nCOV). From the first case reported in December 2019 it is now a pandemic situation and a major public health emergency. The COVID-19 transmission rate is very high, infecting two to three persons on average with contact to an already infected person. There is a need for the health system, specially in developing countries such as in Pakistan, to combat such a novel disease by rapid, accurate, and high quality diagnostic testing in order to screen suspected cases and also surveillance of the disease. A rapid, accurate and low-cost diagnostic point-of-care device is needed for timely diagnosis of COVID-19 and is essential to combat such outbreaks for compelling preventive measures against the disease spread. This review is to highlight the importance of point-of-care diagnostics device for robust and accurate diagnosis of COVID-19 in physician offices and other urgent healthcare-type settings and encourage academics and stake holders towards advancement in order to control outbreaks and develop the public health surveillance system.
Collapse
Affiliation(s)
- S. Ahmad
- College of Medical technology MTI- BKMC Mardan, Khyber Pakhtunkhwa, Pakistan,Corresponding author
| | - N. Ali
- College of Medical technology MTI- BKMC Mardan, Khyber Pakhtunkhwa, Pakistan
| | - M. Kausar
- Rehman College of Allied Health Sciences, Peshawar, Khyber Pakhtunkhwa, Pakistan
| | - H. Misbah
- North West General Hospital and Research Center, Peshawar, Khyber Pakhtunkhwa, Pakistan
| | - A. Wahid
- Rehman College of Allied Health Sciences, Peshawar, Khyber Pakhtunkhwa, Pakistan
| |
Collapse
|
|
190
|
|